<DOC>
	<DOCNO>NCT02463448</DOCNO>
	<brief_summary>This prospective , open-label , Phase 1 , single center study evaluate safety efficacy autologous muscle derive cell treatment chronic underactive bladder .</brief_summary>
	<brief_title>Autologous Muscle Derived Cells Underactive Bladder</brief_title>
	<detailed_description>Subject meet inclusion exclusion criterion consent enrolled study . Initial screen include blood urine testing , questionnaire , physical examination , specialized bladder function test review medical history . At next visit small sample subject 's thigh muscle obtain needle biopsy . This cell biopsy send specialized lab growth processing . Approximately ten week later freeze cell send back treatment site thawing , dilute injection light instrumentation subject 's bladder wall . The subject follow 6 month time may eligible second injection cell . The study doctor determine second injection may beneficial subject . All subject follow 24 month . The long term follow-up assessment 12 , 18 24 month include questionnaire , urine blood testing , specialize bladder function test visualize inside bladder light instrument ( 12 month assessment ) .</detailed_description>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Retention</mesh_term>
	<criteria>1 . Males female , least 18 year age 2 . History Underactive Bladder ( UAB ) least 6 month document medical record 3 . Recurring UAB symptom 4 . Subjects unresponsive relief symptom UAB previous use medication and/or treatment 5 . Voiding difficulty ( complain difficulty empty bladder ) 6 . Post void residual &gt; 150 mL 7 . Total UAB Questionnaire Score &gt; 3 8 . Females childbearing potential agree use reliable form birth control entire study duration 9 . Willing capable understanding complying requirement protocol , include proper completion void diary selfadministered questionnaire 1 . Pregnant , plan become pregnant lactate 2 . History bleed diathesis , uncorrectable coagulopathy , would refuse blood transfusion 3 . Currently anticoagulant therapy 4 . Obvious neurological impairment 5 . Known allergy hypersensitivity bovine proteins allergen , gentamicin sulfate , ampicillin medically warrant exclusion determine physician 6 . Simultaneously participate another investigational drug device study use investigational drug ( ) therapeutic device ( ) within 3 month precede enrollment 7 . Has treat investigational device , drug , procedure UAB within last 6 month . 8 . Medical condition disorder may limit life expectancy may cause protocol deviation ( e.g . unable perform selfevaluations and/or accurately report medical history , urinary symptom , and/or data ) 9 . History cancer pelvic organ , ureter , kidney cancer undergone treatment within past 12 month 10 . Compromised immune system due disease state , chronic corticosteroid use , immunosuppressive therapy 11 . History radiation therapy bladder 12 . Tests positive Hepatitis B ( Hepatitis B Surface Antigen ) , Hepatitis C ( AntiHepatitis C virus enzyme immunoassay , and/or human immunodeficiency virus ( HIV ) 13 . Abnormal renal function 14 . An active urinary tract infection evidence positive urine culture 15 . Taking medication ( ) affect urination ( e.g . medically necessary , stable drug ) prescription drug , overthecounter drug , dietary supplement , include herbal supplement take teas 16 . Requires concomitant use treatment immunosuppressive agent 17 . Pelvic organ prolapse beyond introitus ( e.g. , cystocele , rectocele ) 18 . Abnormal bladder capacity ( i.e. , less 100 mL )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Underactive Bladder</keyword>
</DOC>